Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.
Kantor B, Tagliafierro L, Gu J, Zamora ME, Ilich E, Grenier C, Huang ZY, Murphy S, Chiba-Falek O
Mol Ther. 2018 Nov 7;26(11):2638-2649. doi: 10.1016/j.ymthe.2018.08.019. Epub 2018 Aug 29.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 239792 | pBK1838 | pAAV-CMV-SNCAintron1-AlphaSyn[A53T]-WPRE-SV40pA (PD-INDUCER) |
| 239793 | pBK1575 | pLV-U6-[empty]-EFSNC-dSaCas9-[empty linker]-P2A-Puro-WPRE |
| 239794 | pBK1579 | pLV-U6-[empty]-EFSNC-dSaCas9-DNMT3a-P2A-Puro-WPRE |
| 239796 | pBK1576 | pLV-U6-[empty]-EFSNC-dSaCas9-KRAB-MeCp2-P2A-Puro-WPRE (no gRNA vector) |
| 239797 | pBK1841 | pLV-U6-[SNCAintron1 gRNA 1]-EFSNC-dSaCas9-KRAB-MeCp2-P2A-Puro-WPRE (THERAPEUTIC VECTOR) |
| 239839 | pBK546 | pLV-U6-[hSNCA gRNA 4]-EFSNC-dSpCas9-DNMT3a-P2A-PURO-WPRE |
| 239840 | pBK1837 | 7. BK1837- pLV-CMV-SNCAintron1-AlphaSyn-d2EGFP-P2A-NLuc-SV40-Puro-WPRE |